XIAOZHEN WANG, n/a

VP
Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
Shanghai, China (People's Republic)

Disclosure information not submitted.

Presentation(s):

• SAT-233 - Gensci134, A Long-Acting GHR-Agonistic VHH-Fc Fusion Protein, Demonstrates Sustained GH-Mimetic Activity and Enhanced Metabolic and Skeletal Effects in Preclinical Models

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SUN-180 - Gensci155, A Novel Long-Acting IGF-1 Analog Ameliorates Hyperoxia-Induced Bronchopulmonary Dysplasia in A Neonatal Rat Model

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• SUN-209 - Gensci155, A Novel Long-Acting IGF-1 Analog for the Treatment of Severe Primary IGF‑1 Deficiency with Lower Hypoglycemic Risk and Superior Efficacy

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• SUN-741 - Gensci144, A Novel SLC6A19 Inhibitor, Demonstrates Renoprotective Efficacy in A Humanized SLC6A19 Mouse Model of Aristolochic Acid Nephropathy

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT